325 results on '"Gironella, Mercedes"'
Search Results
2. Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study
3. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
4. Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas
5. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
6. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
7. Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real‐world setting.
8. Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma
9. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
10. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
11. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
12. MM-459 Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis
13. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
14. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
15. P-367 High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
16. P937: CARFILZOMIB, LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: UPDATE ANALYSIS OF REAL-LIFE EXPERIENCE OF GEMMAC GROUP.
17. PB2137: SOCIO-DEMOGRAPHIC FEATURES AND TREATMENT PATTERNS OF MULTIPLE MYELOMA PATIENTS IN SPAIN: AN INTERIM ANALYSIS OF DORIANT STUDY
18. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
19. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role
20. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
21. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
22. #2634 ROLE OF LIGHT CHAIN CLEARANCE IN THE RECOVERY OF RENAL FUNCTION IN MULTIPLE MYELOMA: ANOTHER POINT OF VIEW
23. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV ‐2 booster vaccination in hematologic neoplasms
24. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
25. Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre.
26. Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view
27. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
28. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
29. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM
30. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
31. Clinical and Demographic Characteristics of Multiple Myeloma Patients at Study Enrollment: Analysis of Doriant Study (NCT:04659798)
32. Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
33. Poster: MM-459 Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis
34. Oral Abstract: MM-459 Safety and Clinical Activity of Belantamab Mafodotin with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis
35. MM-488 Iberdomide, Bortezomib, and Dexamethasone (IberVd) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Results From the CC-220-MM-001 Trial
36. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
37. 5q− syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide
38. Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis.
39. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain
40. Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role
41. Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints
42. Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies
43. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
44. Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review
45. Mastocytosis in the skin accompanied by pseudo‐Kaposi’s sarcoma
46. Assessment of amyloid deposits by 18F-florbetapir positron emission tomography
47. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
48. Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality
49. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
50. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.